XRCC1 rs25487基因多态性对于ⅢB~Ⅳ期非小细胞肺癌患者使用铂类联合方案无进展生存期的影响

Influence of XRCC1 rs25487 gene polymorphism on progression-free survival of stageⅢB-ⅣNSCLC patients with platinum-based chemotherapy

目的:探讨X线修复交错互补基因1(XRCC1)rs25487基因多态性对于晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者使用铂类联合方案无进展生存期的影响。方法:收集中国科学技术大学附属第一医院(安徽省立医院)2020年8月—2022年4月期间收治的ⅢB~Ⅳ期NSCLC患者血液标本并行XRCC1 rs25487基因型鉴定,随访其铂类联合方案治疗无进展生存期并记录性别、年龄、病理类型、肿瘤转移部位等临床特征,分析患者基因表型对于预后的影响。结果:该研究共纳入93例患者,Log-rank检验结果显示,XRCC1 rs25487 GG型患者中位PFS显著优于AG/AA型患者(100.0 d vs.79.0 d,P=0.0445)。COX多因素回归结果显示XRCC1 rs25487基因型为患者使用铂类联合方案治疗PFS的独立影响因素(P=0.0285)。结论:晚期NSCLC患者可通过检测XRCC1 rs25487表型预测其铂类治疗的敏感性,为临床治疗决策提供有效参考。

OBJECTIVE To investigate the influence of X-ray repair cross complementing gene 1 XRCC1 rs25487 polymorphism on progression-free survival of patients with stageⅢB-Ⅳnon-small cell lung cancer with platinum-based chemotherapy.METHODS Blood samples were collected from patients with stageⅢB-ⅣNSCLC who were admitted to The First Affiliated Hospital of USTC from August 2020 to April 2022,and their XRCC1 rs25487 genotype was identified.The progression-free survival time of the patients with platinum-based chemotherapy was followed up,and clinical characteristics such as gender,age,pathological type,and tumor metastasis site were recorded.The impact of XRCC1 rs25487 genotype on the prognosis of patients was analyzed.RESULTS A total of 93 patients were included in this study.Log-rank test results showed that the median PFS of XRCC1 rs25487 GG patients was significantly better than that of AG/AA patients(100.0 d vs.79.0 d,P=0.0445).The results of COX multivariate regression showed that XRCC1 rs25487 genotype was an independent factor for PFS of patients with platinum-based combination therapy(P=0.0285).CONCLUSION Advanced NSCLC patients should detect XRCC1 rs25487 phenotype in order to predict their sensitivity of platinum,which can provide effective reference for clinical treatment decisions.